Marina Biotech
Patient Centric Care for Hypertension and Pain
Business Model:
Revenue: $0
Employees: 11-50
Rankings
Industries / Tags:
Detailed Marina Biotech Information
Geographic Data
Address:
City: City Of Industry
State: California
Zip:
Country: United States
Financial Info
Stage:
post ipo equity
Raised Last:
$2M
Raised Total:$20M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Our mission is to provide effective and patient centric treatment for hypertension- including resistant hypertension. In doing so creating a universal platform for the effective treatment of hypertension as well as for the distribution of fixed dose combination [FDC] hypertensive drugs such as Prestalia® and those in our pipeline. The company commercial product Prestalia® is approved by US FDA for the treatment of hypertension and being commercialized through the DyrctAxess platform. The company is also developing and commercializing late stage, non-addictive pain therapeutics. The company’s ‘next-generation of celecoxib,’ including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combatting the opioid epidemic.
Contact Phone:
Contact Email:
Marina Biotech went public on 1/10/2003 on the OTCQB
Listed Exchange:
OTCQB
IPO Date:
1/10/2003
Ticker Symbol:
MRNA
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 3/2018 | Post-IPO Equity | 1 | - |
Thynk Capital, LLC. Thynk Capital, LLC. |
8/2015 | Post-IPO Equity | $1.1M | 2/2014 | Post-IPO Equity | 1 | $6M |
Steven T. Newby Steven T. Newby |
6/2016 | Post-IPO Equity | $300k | 9/2003 | Post-IPO Equity | $11M | 7/2018 | Post-IPO Equity | $1.5M | 3/2018 | Post-IPO Equity | 1 | - |
Thynk Capital, LLC. Thynk Capital, LLC. |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 7/2017 | DyrctAxess | |
| 7/2010 | Novosom | |
| 4/2010 | Cequent Pharmaceuticals |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
